[Clinical study on intravenous infusion of micronomicin].
In recent years, aminoglycoside agents as well as beta-lactam antibiotics have been increasingly used with increased incidence of opportunistic infection caused mainly by Gram-negative bacteria. Therefore, we administered micronomicin sulfate (MCR), reportedly lower in nephrotoxicity, at doses of 60 and 120 mg by intravenous drip infusion for 1 and 2 hours to healthy male volunteers and determined the blood level and the urinary recovery rate. The peak of blood level after 1 hour infusion of MCR was 7.3 micrograms/ml in the 60 mg group and 9.5 micrograms/ml in the 120 mg group. T 1/2 (beta) was 3.34 and 2.48 hours respectively. The peak of blood level after 2 hours infusion of MCR was 5.7 micrograms/ml in the 60 mg group and 8.7 micrograms/ml in the 120 mg group. T 1/2 (beta) was 3.36 and 3.71 hours respectively. In the 120 mg group, the urinary recovery rate for the first 24 hours was 53.5% after 1 hour infusion and 60.9% after 2 hours infusion. In the 60 mg group, the rate was higher, 90.1 and 98.6% respectively. It was suggested that intravenous drip infusion of 120 mg of MCR for 1 hour is comparable to intramuscular injection of the same dose. Further, safety and effectiveness of this drug were studied in 7 clinical cases of urological infection. Good results were obtained in 7 clinical cases given 60 or 120 mg of MCR by intravenous drip infusion. Neither side effects nor abnormal laboratory findings were observed in clinical cases.